Keyphrases
Acute Lymphoblastic Leukemia
100%
Adverse Events
16%
Antibody-drug Conjugate
16%
Antileukemic Activity
33%
CD22
50%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
Complete Response
16%
Confidence Interval
83%
Dose Escalation
16%
Dose Level
83%
Dose-limiting Toxicity
83%
Gemtuzumab Ozogamicin
100%
Heavily Pretreated
16%
Hematopoietic Stem Cell Transplantation
16%
Maximum Permissible Concentration
16%
Minimal Residual Disease
16%
Overall Response Rate
16%
Overall Survival
16%
Pediatric
100%
Pediatric Patients
16%
Pharmacokinetics
16%
Phase 1 Study
100%
Protocol Amendments
16%
Recommended Phase 2 Dose
33%
Relapsed or Refractory
100%
Sinusoidal Obstruction Syndrome
16%
Subsequent Chemotherapy
16%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Adverse Event
16%
Antibody-Drug Conjugate
16%
Chemotherapy
16%
Chimeric Antigen Receptor T-Cell
16%
Hematopoietic Stem Cell Transplantation
16%
Inotuzumab Ozogamicin
100%
Liver Venoocclusive Disease
16%
Minimal Residual Disease
16%
Overall Survival
16%
Pediatrics
100%
Pediatrics Patient
16%
Pharmacokinetics
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Adverse Event
16%
Antibody Drug Conjugate
16%
Chemotherapy
16%
Chimeric Antigen Receptor
16%
Inotuzumab Ozogamicin
100%
Liver Venoocclusive Disease
16%
Minimal Residual Disease
16%
Overall Survival
16%
Pharmacokinetics
16%
Biochemistry, Genetics and Molecular Biology
CD22
100%
Chimeric Antigen Receptor
33%
Conjugate
33%
Hematopoietic Stem Cell Transplantation
33%
Overall Survival
33%
Pharmacokinetics
33%
T Cell
33%
Immunology and Microbiology
Antibody Drug Conjugate
16%
CD22
50%
Chimeric Antigen Receptor T-Cell
16%
Hematopoietic Stem Cell Transplantation
16%
Inotuzumab Ozogamicin
100%
Overall Survival
16%
Pharmacokinetics
16%